Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017477 | 0.80 | AR (0.46) | KDM4EMAPTALDH1A1MEN1POLB | |
| SCHEMBL12017485 | 0.79 | MCL1 (0.52) | SLC6A4SLC6A2SLC6A3PKMHTR2A | |
| SCHEMBL3145757 | 0.76 | HSPA5 (0.52) | PKMMAPT | |
| SCHEMBL12017473 | 0.76 | PARP1 (0.40) | SLC6A4SLC6A2SLC6A3KDM4ECYP3A4 | |
| SCHEMBL5816301 | 0.76 | C1R (0.38) | — | |
| SCHEMBL9057228 | 0.76 | AR (0.43) | CYP3A4ALDH1A1 | |
| SCHEMBL7822927 | 0.76 | TAAR1 (0.41) | MEN1KMT2A | |
| SCHEMBL1680621 | 0.76 | — | — | |
| SCHEMBL12017487 | 0.75 | LTA4H (0.44) | SLC6A4SLC6A2SLC6A3PKMLTA4H | |
| SCHEMBL3149895 | 0.75 | AR (0.47) | KDM4EMAPTALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | SLC6A4 94/4885SLC6A2 40/4885SLC6A3 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.